• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 28th October 2013

Personalised Medicine: Economic Incentives for Evidence Generation

Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the University of Washington, summarise the critical economic issues in the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine

Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine.

Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the University of Washington, summarise the critical economic issues in the development of evidence of value for drugs and diagnostics that are part of personalised medicine.

Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine

Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the University of Washington, summarise the critical economic issues in the development of evidence of value for drugs and diagnostics that are part of personalised medicine.[1] Their article draws on the methodological and practical insights of the other contributions in a special supplement of Value in Health that addresses the role of health economics and outcomes research in personalised medicine.

Towse and Garrison note that progress in personalised medicine has been slower than many had hoped, but that clear progress is being made despite continuing scientific challenges. Encouraging more rapid progress in the development and availability of drugs and diagnostics that are essential to personalised medicine requires appropriate sets of economic incentives. Towse and Garrison identify four that they believe are essential to creating the evidence needed to value and most efficiently use drugs and diagnostics. These are:

  1. Pricing by payers that reflects value. This includes acceptance of the potential for pricing the same drug differently for particular populations as well as pricing for diagnostics that is based on their value to improving care, not just on their cost
  2. Some form of intellectual property protection or data exclusivity for diagnostics. Encouraging investment in evidence generation not only will create better data on clinical utility, but also can reward bringing higher-quality tests to market.
  3. Realistic expectations about standards of evidence. Data collection before the launch of a drug or diagnostic is limited by a number of considerations; allowing coverage with reasonable requirements for developing new evidence based on actual clinical practice can provide crucial additional data.
  4. Public investment in evidence collection that complements the efforts of payers and manufacturers. This recognizes that economic incentives alone are not likely to be sufficient for some important questions.

Tackling the scientific challenges requires, according to the authors, adjustments in the current pricing, evidence and intellectual property approaches. Essential is “building and maintaining a balance” across three sets of factors:

  1. Realistic evidence thresholds and payers’ needs for confidence in the clinical utility of the drugs and devices they purchase
  2. Payment for drugs and devices that both reflects value and promotes cost-effectiveness in health systems
  3. Enough intellectual property protection to both generate needed evidence at an acceptable cost and encourage the competition that can lead to “better and more efficient” tests.

Creating a positive economic environment, then, is an important component of fostering continuous advances in the science.


[1] The authors restrict the use of the term “personalised medicine” to defining and identifying subgroups of patients using biomarker-based diagnostic tests.

Towse, A. and Garrison, L.P. (2013) Economic incentives for evidence generation: Promoting an efficient path to personalized medicine. Value in Health. 16(6 Suppl), S39-S43. doi: 10.1016/j.jval.2013.06.003.


Other recent OHE activities on the topic of personalised, stratified or precision medicines include:

  • Towse’s and Garrison’s contributions to the July 2013 Academy of Medical Sciences Report, Realising the potential of stratified medicines, available for download from the AMS website.
  • Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10(1), 61-72. An earlier version is available as a Research Paper 12/03.
  • Mattison, N. ed. (2013) The challenges and economics of drug development in 2022. London: Office of Health Economics.
  • Towse’s analysis of valuing stratified/personalised medicine is contained in this short video: Challenges in valuing genomic medicines.
 
  • Health Technology Assessment…
  • Economics of Innovation
  • External Publications

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!